NDC 13548-132 Acanya

Clindamycin Phosphate And Benzoyl Peroxide

NDC Product Code 13548-132

NDC CODE: 13548-132

Proprietary Name: Acanya What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Clindamycin Phosphate And Benzoyl Peroxide What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • This combination medication is used to treat a certain type of acne (inflammatory acne vulgaris). It helps to decrease the number of acne pimples. Clindamycin is an antibiotic that stops the growth of acne-causing bacteria. Benzoyl peroxide can also stop the growth of bacteria as well as reduce oil production in the skin, helping keep your pores open.

NDC Code Structure

  • 13548 - Bausch Health Us, Llc

NDC 13548-132-50

Package Description: 1 BOTTLE, PUMP in 1 CARTON > 50 g in 1 BOTTLE, PUMP

Price per Unit: $10.05866 per GM

NDC Product Information

Acanya with NDC 13548-132 is a a human prescription drug product labeled by Bausch Health Us, Llc. The generic name of Acanya is clindamycin phosphate and benzoyl peroxide. The product's dosage form is gel and is administered via topical form.

Dosage Form: Gel - A semisolid3 dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion.4 A gel may contain suspended particles.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Acanya Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.


Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • WATER (UNII: 059QF0KO0R)
  • CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: 4Q93RCW27E)
  • PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
  • POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Decreased Sebaceous Gland Activity - [PE] (Physiologic Effect)
  • Lincosamide Antibacterial - [EPC] (Established Pharmacologic Class)
  • Lincosamides - [CS]
  • Neuromuscular Blockade - [PE] (Physiologic Effect)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Bausch Health Us, Llc
Labeler Code: 13548
FDA Application Number: NDA050819 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 07-26-2010 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Information for Patients

Clindamycin and Benzoyl Peroxide Topical

Clindamycin and Benzoyl Peroxide Topical is pronounced as (klin da mye' sin) (ben' zoe ill) (per ox' ide)

Why is clindamycin and benzoyl peroxide topical medication prescribed?
The combination of clindamycin and benzoyl peroxide is used to treat acne. Clindamycin and benzoyl peroxide are in a class of medications called topical antibiotics. The ...
[Read More]

* Please review the disclaimer below.

Acanya Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

ACANYA® Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older.

2 Dosage And Administration

Before applying ACANYA Gel, wash your face gently with a mild soap, rinse with warm water, and pat your skin dry.Apply a pea-sized amount of ACANYA Gel to the face once daily. Avoid the eyes, mouth, mucous membranes, or areas of broken skin.Use of ACANYA Gel beyond 12 weeks has not been evaluated.Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents.ACANYA Gel is not for oral, ophthalmic, or intravaginal use.

3 Dosage Forms And Strengths

Gel, 1.2%/2.5%Each gram of ACANYA Gel contains 10 mg (1%) clindamycin as phosphate, and 25 mg (2.5%) benzoyl peroxide in a white to off-white, opaque, smooth gel.

4.1 Hypersensitivity

ACANYA Gel is contraindicated in those individuals who have shown hypersensitivity to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. Anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in postmarketing use with ACANYA Gel [see Postmarketing Experience (6.2)].

4.2 Colitis/Enteritis

ACANYA Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis [see Warnings and Precautions (5.1)].

5.1 Colitis

Systemic absorption of clindamycin has been demonstrated following topical use of clindamycin. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. When significant diarrhea occurs, ACANYA Gel should be discontinued.Severe colitis has occurred following oral and parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.Studies indicate toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.

5.2 Ultraviolet Light And Environmental Exposure

Minimize sun exposure including use of tanning beds or sun lamps following drug application.

5.3 Concomitant Topical Medications

Concomitant topical acne therapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritancy or dermatitis occurs, reduce frequency of application or temporarily interrupt treatment and resume once the irritation subsides. Treatment should be discontinued if the irritation persists.

6.1 Clinical Trials Experience

  • Because clinical trials are conducted under widely varying conditions, adverse reactions observed in the clinical trials of a drug cannot always be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The following selected adverse reactions occurred in less than 0.2% of subjects treated with ACANYA Gel: application site pain (0.1%); application site exfoliation (0.1%); and application site irritation (0.1%).During clinical trials, subjects were assessed for local cutaneous signs and symptoms of erythema, scaling, itching, burning and stinging. Most local skin reactions increased and peaked around Week 4 and continually decreased over time reaching near baseline levels by Week 12. The percentage of subjects that had symptoms present before treatment, the maximum value recorded during treatment, and the percent with symptoms present at Week 12 are shown in Table 1.Table 1: Percent of Subjects with Local Skin Reactions. Combined Results from the Two Phase 3 Trials (N = 773) Before Treatment(Baseline)Maximum DuringTreatmentEnd of Treatment(Week 12)MildMod.*SevereMildMod.*SevereMildMod.*Severe Erythema 22 4 0 25 5 < 1 15 2 0 Scaling 8 < 1 0 18 3 0 8 1 0 Itching 10 2 0 15 2 0 6 < 1 0 Burning 3 < 1 0 8 2 0 2 < 1 0 Stinging 2 < 1 0 6 1 0 1 < 1 0

6.2 Postmarketing Experience

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Anaphylaxis, as well as allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide.

7.1 Erythromycin

ACANYA Gel should not be used in combination with topical or oral erythromycin-containing products due to its clindamycin component. In vitro studies have shown antagonism between erythromycin and clindamycin. The clinical significance of this in vitro antagonism is not known.

7.2 Neuromuscular Blocking Agents

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ACANYA Gel should be used with caution in patients receiving such agents.

8.1 Pregnancy

Risk SummaryThere are no available data on ACANYA Gel use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. The limited published data on use of clindamycin in pregnant women with exposure during the first trimester are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes (see Data).In limited published clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of major birth defects.In animal reproduction studies, clindamycin did not cause malformations or embryo-fetal development toxicity in pregnant rats and mice when administered during the period of organogenesis at systemic doses up to 240 times the maximum recommended human dose (MRHD) of 2.5 g ACANYA Gel, based on body surface area (BSA) comparisons (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss, and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.DataHuman DataIn limited published trials in pregnant women administered clindamycin during the first trimester of pregnancy, there was no difference in the rate of major birth defects reported among in utero exposed infants compared to unexposed infants. These data cannot definitely establish or exclude any clindamycin-associated risk during pregnancy.Animal DataAnimal reproductive/developmental toxicity studies have not been conducted with ACANYA Gel or benzoyl peroxide. Developmental toxicity studies of clindamycin performed in pregnant rats and mice administered during the period of organogenesis at oral doses of up to 600 mg/kg/day (240 and 120 times the MRHD for, respectively, based on BSA comparisons) or subcutaneous doses of up to 200 mg/kg/day (80 and 40 times the MRHD for clindamycin, respectively, based on BSA comparisons) revealed no malformations or embryo-fetal development toxicity.

8.2 Lactation

Risk SummaryThere are no data on the presence of clindamycin or benzoyl peroxide in human milk, the effects on the breastfed child, or the effects on milk production following topical administration. However, clindamycin has been reported to be present in breast milk in small amounts following oral and parenteral administration. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ACANYA Gel and any potential adverse effects on the breastfed child from ACANYA Gel or from the underlying maternal condition.Clinical ConsiderationsIf used during lactation and ACANYA Gel is applied to the chest, care should be taken to avoid accidental ingestion by the infant.

8.4 Pediatric Use

Safety and effectiveness of ACANYA Gel in pediatric patients under the age of 12 have not been evaluated.

8.5 Geriatric Use

Clinical trials of ACANYA Gel did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.

11 Description

  • ACANYA (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5% is a combination product with two active ingredients in a white to off-white, opaque, smooth, aqueous gel formulation intended for topical use. Clindamycin phosphate is a water-soluble ester of the semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)‑hydroxyl group of the parent antibiotic lincomycin.The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate). The structural formula for clindamycin phosphate is represented below:Clindamycin phosphate: Molecular Formula: C18H34ClN2O8PSMolecular Weight: 504.97Benzoyl peroxide is an antibacterial and keratolytic agent. The structural formula for benzoyl peroxide is represented below:Benzoyl peroxide: Molecular Formula: C14H10O4Molecular Weight: 242.23ACANYA Gel contains the following inactive ingredients: carbomer 980, potassium hydroxide, propylene glycol, and purified water. Each gram of ACANYA Gel contains 1.2% of clindamycin phosphate which is equivalent to 1% clindamycin.

12.1 Mechanisms Of Action

Clindamycin: Clindamycin is a lincosamide antibacterial [see Microbiology (12.4)].Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action is unknown.

12.3 Pharmacokinetics

The systemic absorption of clindamycin was investigated in an open-label, multiple-dose trial in 16 adult subjects with moderate to severe acne vulgaris treated with 1 gram of ACANYA Gel applied to the face once daily for 30 days. Twelve subjects (75%) had at least one quantifiable clindamycin plasma concentration above the lower limit of quantification (LOQ = 0.5 ng/mL) on Day 1 or Day 30. On Day 1, the mean (± standard deviation) peak plasma concentration (Cmax) was 0.78 ± 0.22 ng/mL (n=9 with measurable concentrations), and the mean AUC0-t was 5.29 ± 0.81 h.ng/mL (n=4). On Day 30, the mean Cmax was 1.22 ± 0.88 ng/mL (n=10), and the mean AUC0-t was 8.42 ± 6.01 h.ng/mL (n=6). Clindamycin plasma concentrations were below LOQ in all subjects at 24 hours post-dose on the three tested days (Day 1, 15, and 30).Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid.

12.4 Microbiology

Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing bacterial protein synthesis.Clindamycin and benzoyl peroxide individually have been shown to havein vitro activity against Propionibacterium acnes, an organism which has been associated with acne vulgaris; however, the clinical significance of this activity against P. acnes is not known.P. acnes resistance to clindamycin has been documented. Resistance to clindamycin is often associated with resistance to erythromycin.

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

Carcinogenicity, mutagenicity, and impairment of fertility testing of ACANYA Gel have not been performed.Benzoyl peroxide has been shown to be a tumor promoter and progression agent in a number of animal studies. Benzoyl peroxide in acetone at doses of 5 and 10 mg administered topically twice per week for 20 weeks induced skin tumors in transgenic Tg.AC mice. The clinical significance of this is unknown.Carcinogenicity studies have been conducted with a gel formulation containing 1% clindamycin and 5% benzoyl peroxide. In a 2-year dermal carcinogenicity study in mice, treatment with the gel formulation at doses of 900, 2700, and 15000 mg/kg/day (1.8, 5.4, and 30 times the MRHD for clindamycin and 3.6, 10.8, and 60 times the MRHD for benzoyl peroxide, respectively, based on BSA comparisons) did not cause any increase in tumors. However, topical treatment with a different gel formulation containing 1% clindamycin and 5% benzoyl peroxide at doses of 100, 500, and 2000 mg/kg/day caused a dose-dependent increase in the incidence of keratoacanthoma at the treated skin site of male rats in a 2-year dermal carcinogenicity study in rats. In an oral (gavage) carcinogenicity study in rats, treatment with the gel formulation at doses of 300, 900, and 3000 mg/kg/day (1.2, 3.6, and 12 times the MRHD for clindamycin and 2.4, 7.2, and 24 times the MRHD for benzoyl peroxide, respectively, based on BSA comparisons) for up to 97 weeks did not cause any increase in tumors.Clindamycin phosphate was not genotoxic in the human lymphocyte chromosome aberration assay. Benzoyl peroxide has been found to cause DNA strand breaks in a variety of mammalian cell types, to be mutagenic in S. typhimurium tests by some but not all investigators, and to cause sister chromatid exchanges in Chinese hamster ovary cells.Fertility studies have not been performed with ACANYA Gel or benzoyl peroxide, but fertility and mating ability have been studied with clindamycin. Fertility studies in rats treated orally with up to 300 mg/kg/day of clindamycin (approximately 120 times the MRHD for clindamycin, based on BSA comparisons) revealed no effects on fertility or mating ability.

14 Clinical Studies

  • The safety and efficacy of once daily use of ACANYA Gel were assessed in two 12-week multi-center, randomized, blinded trials in subjects 12 years and older with moderate to severe acne vulgaris. The two trials were identical in design and compared ACANYA Gel to clindamycin in the vehicle gel, benzoyl peroxide in the vehicle gel, and the vehicle gel alone.The co-primary efficacy variables were:1.Mean absolute change from baseline at Week 12 in:2.Inflammatory lesion counts3.Non-inflammatory lesion counts4.Percent of subjects who had a 2-grade improvement from baseline on an Evaluator’s Global Severity (EGS) score.The EGS scoring scale used in all of the clinical trials for ACANYA Gel is as follows:GradeDescription Clear Normal, clear skin with no evidence of acne vulgaris AlmostClear Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red) Mild Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulocystic lesions) Moderate Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one small nodulocystic lesion Severe Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be a few nodulocystic lesions VerySevere Highly inflammatory lesions predominate, variable number of comedones, many papules/pustules and many nodulocystic lesionsThe results of Trial 1 at Week 12 are presented in Table 2:Table 2: Trial 1 ResultsACANYA GelClindamycinGelBenzoylPeroxide GelVehicle GelTrial 1N = 399N = 408N = 406N = 201 EGSS Clear or Almost Clear 115 (29%) 84 (21%) 76 (19%) 29 (14%) 2-grade reduction from baseline 131 (33%) 100 (25%) 96 (24%) 38 (19%) Inflammatory Lesions:   Mean absolute change 14.8 12.2 13.0 9.0   Mean percent (%) reduction 55.0% 47.1% 49.3% 34.5% Non-Inflammatory Lesions:   Mean absolute change 22.1 17.9 20.6 13.2   Mean percent (%) reduction 45.3% 38.0% 40.2% 28.6%The results of Trial 2 at Week 12 are presented in Table 3:Table 3: Trial 2 ResultsACANYA GelClindamycinGelBenzoyl Peroxide GelVehicle GelTrial 2N = 398N = 404N = 403N = 194 EGSS Clear or Almost Clear 113 (28%) 94 (23%) 94 (23%) 21 (11%) 2-grade reduction from baseline 147 (37%) 114 (28%) 114 (28%) 27 (14%) Inflammatory Lesions:   Mean absolute change 13.7 11.3 11.2 5.7   Mean percent (%) reduction 54.2% 45.3% 45.7% 23.3% Non-Inflammatory Lesions:   Mean absolute change 19.0 14.9 15.2 8.3   Mean percent (%) reduction 41.2% 34.3% 34.5% 19.2%

16.1 How Supplied

ACANYA Gel, 1.2%/2.5%, a white to off-white smooth gel is supplied as:NDC 13548-132-50                   50 g pump

16.2 Dispensing Instructions For The Pharmacist

  • •Dispense ACANYA Gel with a 10-week expiration date. •Specify “Store at room temperature up to 25°C (77°F). Do not freeze.”

16.3 Storage And Handling

  • •PHARMACIST: Prior to Dispensing: Store in a refrigerator, 2° to 8°C (36° to 46°F). •PATIENT: Store at room temperature at or below 25°C (77°F). •Protect from freezing. •Store pump upright. •Keep out of the reach of children. •Keep container tightly closed.

17 Patient Counseling Information

  • Advise the patient to read the FDA-approved patient labeling (Patient Information). •Patients who develop allergic reactions such as severe swelling or shortness of breath should discontinue use and contact their physician immediately. •ACANYA Gel may cause irritation such as erythema, scaling, itching, or burning, especially when used in combination with other topical acne therapies. •Excessive or prolonged exposure to sunlight should be limited. To minimize exposure to sunlight, a hat or other clothing should be worn. Sunscreen may also be used. •ACANYA Gel may bleach hair or colored fabric.Distributed by:Bausch Health US, LLCBridgewater, NJ 08807 USAManufactured by:Bausch Health Companies Inc.Laval, Quebec H7L 4A8, CanadaU.S. Patent Numbers: 8,288,434; 8,663,699; 8,895,070; 9,078,870; 10,220,049 and 10,624,918ACANYA is a trademark of Bausch Health Companies Inc. or its affiliates.© 2020 Bausch Health Companies Inc. or its affiliates9387203

Patient Package Insert

  • PATIENT INFORMATION ACANYA®(AH-CAN΄-YAH)(clindamycin phosphate and benzoyl peroxide)gel, 1.2%/2.5%Important information: ACANYA Gel is for use on skin only (topical use). Do not use ACANYA Gel in your mouth, eyes, or vagina. What is ACANYA Gel? ACANYA Gel is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years of age and older.  It is not known if ACANYA Gel is safe and effective for use longer than 12 weeks. It is not known if ACANYA Gel is safe and effective in children under 12 years of age. Do not use ACANYA Gel if you have: •had an allergic reaction to clindamycin, benzoyl peroxide, lincomycin or any of the ingredients in ACANYA Gel. See the end of this leaflet for a complete list of ingredients in ACANYA Gel. •Crohn’s disease or ulcerative colitis. •had inflammation of the colon (colitis), or severe diarrhea with past antibiotic use. Talk with your doctor if you are not sure if you have any of the conditions listed above. Before using ACANYA Gel, tell your doctor about all of your medical conditions, including if you: •plan to have surgery. ACANYA Gel may affect how certain medicines work that may be given during surgery. •are pregnant or plan to become pregnant. It is not known if ACANYA Gel will harm your unborn baby. •are breastfeeding or plan to breastfeed. It is not known if ACANYA Gel passes into your breast milk. Clindamycin when taken by mouth or by injection has been reported to appear in breast milk. Talk to your doctor about the best way to feed your baby during treatment with ACANYA Gel.Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. ACANYA Gel may affect the way other medicines work and other medicines may affect how ACANYA Gel works. •Especially tell your doctor if you take medicine by mouth that contains erythromycin or use products on your skin that contain erythromycin. ACANYA Gel should not be used with products that contain erythromycin. •Tell your doctor about any skin products you use. Other skin and topical acne products may increase the irritation of your skin when used with ACANYA Gel. Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine. How should I use ACANYA Gel? •Use ACANYA Gel exactly as your doctor tells you to use it. See the detailed “Instructions for Use” for directions about how to apply ACANYA Gel. •Your doctor will tell you how long to use ACANYA Gel. •Apply ACANYA Gel to your face 1 time each day.What should I avoid while using ACANYA Gel? •Limit your time in sunlight. You should avoid using tanning beds or sunlamps during treatment with ACANYA Gel. If you have to be in sunlight, wear a wide-brimmed hat or other protective clothing, and use sunscreen to cover the treated areas. •Avoid getting ACANYA Gel in your hair or on colored fabric. ACANYA Gel may bleach hair or colored fabric.What are possible side effects of ACANYA Gel?ACANYA Gel can cause serious side effects including: •Inflammation of the colon (colitis). Stop using ACANYA Gel and call your doctor right away if you have severe stomach (abdominal) cramps, watery diarrhea, or bloody diarrhea during treatment, and within several weeks after treatment with ACANYA Gel. •Allergic reactions. Stop using ACANYA Gel, call your doctor and get help right away if you have any of the following symptoms during treatment with ACANYA Gel:osevere itchingoswelling of your face, eyes, lips, tongue or throatotrouble breathingThe most common side effects of ACANYA Gel include application site pain, application site irritation including redness, itching, burning, and stinging. Stop using ACANYA Gel and call your doctor if you have a skin rash or your skin becomes very red, itchy or swollen. Talk to your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with ACANYA Gel. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should I store ACANYA Gel? •Store ACANYA Gel at room temperature at or below 77°F (25°C). •Do not freeze ACANYA Gel. •Throw away (discard) ACANYA Gel that has passed the expiration date. •Store pump upright. •Keep the container tightly closed.Keep ACANYA Gel and all medicines out of the reach of children.General information about the safe and effective use of ACANYA Gel. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ACANYA Gel for a condition for which it was not prescribed. Do not give ACANYA Gel to other people, even if they have the same condition you have. It may harm them. You can also ask your doctor or pharmacist for information about ACANYA Gel that is written for healthcare professionals.What are the ingredients in ACANYA Gel?Active Ingredients: clindamycin phosphate and benzoyl peroxide Inactive Ingredients: carbomer 980, potassium hydroxide, propylene glycol, and purified waterDistributed by: Bausch Health US, LLC, Bridgewater, NJ 08807 USAManufactured by: Bausch Health Companies Inc., Laval, Quebec H7L 4A8, CanadaU.S. Patent Numbers: 8,288,434; 8,663,699; 8,895,070; 9,078,870; 10,220,049 and 10,624,918ACANYA is a trademark of Bausch Health Companies Inc. or its affiliates.© 2020 Bausch Health Companies Inc. or its affiliatesFor more information about ACANYA Gel, call 1-800-321-4576.This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 09/2020 9387203

Instructions For Use

  • INSTRUCTIONS FOR USEACANYA®(AH-CAN΄-YAH)(clindamycin phosphate and benzoyl peroxide) gel, 1.2%/2.5%Important Information: ACANYA Gel is for use on skin only (topical use). ACANYA Gel is not for use in your mouth, eyes or vagina.Read this Instructions for Use before you start using ACANYA Gel and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment. •Apply ACANYA Gel to your face 1 time each day as prescribed. •Before you apply ACANYA Gel, wash your face gently with a mild soap, rinse with warm water, and pat your skin dry. •To apply ACANYA Gel to your face, use the pump to dispense one pea-sized amount of ACANYA Gel onto your fingertip. See Figure 1. •One pea-sized amount of ACANYA Gel should be enough to cover your entire face.  Figure 1 •Dot the one pea-sized amount of ACANYA Gel onto six areas of your face (chin, left cheek, right cheek, nose, left forehead, right forehead). See Figure 2.Figure 2 •Spread the gel over your face and gently rub it in. It is important to spread the gel over your entire face. If your doctor tells you to put ACANYA Gel on other areas of your skin with acne, be sure to ask how much you should use. •Wash your hands with soap and water after applying ACANYA Gel.How should I store ACANYA Gel? •Store ACANYA Gel at room temperature at or below 77°F (25°C). •Do not freeze ACANYA Gel. •Throw away (discard) ACANYA Gel that has passed the expiration date. •Store pump upright. •Keep the container tightly closed.Keep ACANYA Gel and all medicines out of the reach of children.Distributed by: Bausch Health US, LLC, Bridgewater, NJ 08807 USA Manufactured by: Bausch Health Companies Inc., Laval, Quebec H7L 4A8, Canada U.S. Patent Numbers: 8,288,434; 8,663,699; 8,895,070; 9,078,870; 10,220,049 and 10,624,918ACANYA is a trademark of Bausch Health Companies Inc. or its affiliates. © 2020 Bausch Health Companies Inc. or its affiliatesThe Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.Issued: 09/20209387203

* Please review the disclaimer below.